arrow_back Back Filing freshness 10-K Q4 FY2026 SEC EDGAR

NEOGEN CORP

NEOG
$11.46 ▲ +0.16 (+1.46%) at close
Healthcare ·In Vitro & In Vivo Diagnostic Substances ·USIn Vitro & In Vivo Diagnostic Substances
66 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
36
Health
Weak
Bearish
auto_awesome

Analytical Summary

NEOGEN CORP faces fundamental challenges with weakness in Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth -0.1%
Op. Margin 1.4%
ROIC 0.1%
FCF / Share None
Trailing P/E
Price / Book 1.2x
FCF Yield
Debt / Equity 0.38
info Valuation on last close. End-of-day price, Aug 7, 2026.

66-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$225.30M
— -0.1%
Net Income Profit after all expenses
$-11.30M
↑ +98.2%
Operating Margin Operating profit as % of sales
1.4%
↑ +188.1% 24th
FCF / Share Free cash flow per share
$0.10
↑ +16.6%
Long-Term Debt Long-term obligations
$793.70M
— +0.1%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability
36
Returns
40
Financial Health
48
Cash Quality
3

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 18 years · 66 quarters